Applications

1342.2 – Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (resubmission)

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type Re-application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Deferred

Application details

Reason for application

New MBS item.

Service or technology in this application

Oncotype DX® is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.

Type: Investigative

Medical condition this application addresses

Outside Australia, Oncotype DX® is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.

Previous applications

1342.1 – Oncotype DX? breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)

Application documents

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: 8 October 2015
  • MSAC meeting: 26 November 2015